🇺🇸 Valganciclovir Tablets in United States

13 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 13

Most-reported reactions

1. Bone Marrow Failure — 2 reports (15.38%)
2. Inflammation — 2 reports (15.38%)
3. Respiratory Failure — 2 reports (15.38%)
4. Abscess — 1 report (7.69%)
5. Anaemia — 1 report (7.69%)
6. Chronic Papillomatous Dermatitis — 1 report (7.69%)
7. Condition Aggravated — 1 report (7.69%)
8. Cystitis Haemorrhagic — 1 report (7.69%)
9. Dermatophytosis — 1 report (7.69%)
10. Disseminated Trichosporonosis — 1 report (7.69%)

Source database →

Frequently asked questions

Is Valganciclovir Tablets approved in United States?

Valganciclovir Tablets does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Valganciclovir Tablets in United States?

Cecilia Soderberg-Naucler is the originator. The local marketing authorisation holder may differ — check the official source linked above.